InMed Pharmaceuticals (OTCMKTS:IMLFF) Shares Down 1.6%

InMed Pharmaceuticals Inc. (OTCMKTS:IMLFFGet Rating)’s stock price fell 1.6% during trading on Monday . The stock traded as low as $3.90 and last traded at $4.88. 63,800 shares traded hands during mid-day trading, an increase of 461% from the average session volume of 11,369 shares. The stock had previously closed at $4.96.

The stock’s fifty day simple moving average is $4.88.

InMed Pharmaceuticals Company Profile (OTCMKTS:IMLFF)

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.